This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A second look at the positive top-line results from the Phase 2 Study of barzolvolimab in chronic spontaneous urticaria.

Ticker(s): CLDX

Who's the expert?

Institution: The Corvallis Clinic

  • Allergist who sees 100 patients with chronic urticaria
  • Works in a multispeciality clinic seeing adult and pediatric patients

Interview Goal
.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.